New funding fuels device-maker’s pursuit of FDA approval

Moximed snagged $40 million as it works to secure approval for its device, an implantable shock absorber for the knee designed to put off the need for full joint replacement. CEO Anton Clifford touts that the MISHA Knee System is the first of its kind.